Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
3.600
+0.200 (5.88%)
At close: May 29, 2025, 4:00 PM
3.570
-0.030 (-0.83%)
After-hours: May 29, 2025, 4:04 PM EDT

Contineum Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--50--
Gross Profit
--50--
Selling, General & Admin
15.913.667.266.636.29
Research & Development
43.1737.2426.6716.0922.36
Operating Expenses
59.0750.8933.9222.7228.65
Operating Income
-59.07-50.8916.08-22.72-28.65
Interest Expense
---0.21-0.39-0.33
Interest & Investment Income
9.528.914.610.760.08
Other Non Operating Income (Expenses)
-0.28-0.272.7-1.91-0.1
Pretax Income
-49.83-42.2623.17-24.25-29
Income Tax Expense
--0.45--
Net Income
-49.83-42.2622.72-24.25-29
Preferred Dividends & Other Adjustments
--19.57--
Net Income to Common
-49.83-42.263.15-24.25-29
Shares Outstanding (Basic)
2519222
Shares Outstanding (Diluted)
2519322
Shares Change (YoY)
981.89%469.95%51.38%6.35%-
EPS (Basic)
-1.98-2.181.36-10.81-13.75
EPS (Diluted)
-1.98-2.180.08-10.81-13.77
Free Cash Flow
-39.7-33.3618.94-20.24-26.43
Free Cash Flow Per Share
-1.57-1.725.58-9.02-12.53
Gross Margin
--100.00%--
Operating Margin
--32.15%--
Profit Margin
--6.29%--
Free Cash Flow Margin
--37.87%--
EBITDA
-58.8-50.6416.27-22.39-28.32
EBITDA Margin
--32.54%--
D&A For EBITDA
0.280.260.20.330.33
EBIT
-59.07-50.8916.08-22.72-28.65
EBIT Margin
--32.15%--
Effective Tax Rate
--1.94%--
Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q